BENJAMIN LEVRON: Open Payments
NPI 1184159501 · BATON ROUGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,059 in 47 payments from 14 companies in 2025. Trend: 2023 $1,273 · 2024 $1,427 · 2025 $1,059
Food & beverage: $1,060
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 11 | $293 |
| Lilly USA, LLC | 7 | $220 |
| ABBVIE INC. | 9 | $141 |
| Axsome Therapeutics, Inc. | 3 | $76 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $59 |
| AstraZeneca Pharmaceuticals LP | 3 | $58 |
| Kowa Pharmaceuticals America, Inc. | 2 | $40 |
| Novo Nordisk Inc | 2 | $38 |
| Amgen Inc. | 2 | $34 |
| Abbott Laboratories | 1 | $31 |
Products named: Yeztugo, ZEPBOUND, UBRELVY, MOUNJARO, Auvelity, CAPLYTA, VRAYLAR, FARXIGA.
Industry payments across LA — which companies pay providers there.
